Advertisement

Topics

Haitong Invests in Orig3n, a Boston Genetics/Regenerative Medicine Company

21:42 EDT 13 Jul 2018 | ChinaBio Today

Haitong International of Hong Kong led the first close of a Series B round in Orig3n, a Boston genetics and regenerative medicine company. The size of the round was not disclosed, but Orig3n has raised $50 million since it was founded in 2014. Orig3n offers personalized genetics tests, and it is developing an allogenic cell bank, mostly from crowdsourced samples, that it will use to advance regenerative treatments for disease. The company expects its partner to discover regenerative treatments for cystic fibrosis, Parkinson's disease and frontotemporal dementia. More details....

Share this with colleagues:

Original Article: Haitong Invests in Orig3n, a Boston Genetics/Regenerative Medicine Company

NEXT ARTICLE

More From BioPortfolio on "Haitong Invests in Orig3n, a Boston Genetics/Regenerative Medicine Company"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...